We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HLXC:NASDAQHelix Acquisition Corp. III Analysis

Data as of 2026-06-13 - not real-time

$10.35

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Technical snapshot: HLXC trades at $10.35, just above its 20‑day ($10.23), 50‑day ($10.23) and 200‑day ($10.23) simple moving averages, while the RSI sits at 68.6 and the MACD shows a bullish signal. Support sits near $10.14 and resistance near $10.57, with volume trending upward but remaining thin (≈1,100 shares vs a 10‑day average of ~39,500).
Fundamental reality: The SPAC reports zero revenue, no earnings, a negative book value per share (-$0.007) and a staggering negative price‑to‑book ratio, leaving valuation largely speculative despite a market cap of $273 M and an extreme‑greed market sentiment.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price marginally above short‑term SMAs suggests limited upside
  • RSI nearing overbought territory
  • Increasing but still low absolute trading volume

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Absence of operating revenue or earnings
  • Negative book value per share and extreme P/B ratio
  • Uncertainty surrounding timing and success of a business combination

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Purely speculative SPAC structure with no underlying assets
  • Potential dilution or loss if merger fails to materialize
  • Market sentiment high but fundamentals fundamentally absent

Key Metrics & Analysis

Financial Health

P/B Ratio-1478.6
Industry P/E16.8

Technical Analysis

TrendBearish
RSI68.6
Support$10.14
Resistance$10.56
MA 20$10.23
MA 50$10.23
MA 200$10.23
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.03
Volatility6.52%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.